In order to investigate the relationship between c-Met protein and TRAIL resistance in brain tumor cells, we first tested a panel of human medulloblastoma (MB) cell lines for their sensitivity to S-TRAIL treatment. The gene discussed is MET; the disease is brain neoplasm.